Natera is the industry growth leader in diagnostics with 39% revenue growth year-over-year, FCF-positive despite GAAP losses, and a Rule of 40 score of 44, but faces three consecutive earnings misses and a low asymmetry ratio at current price levels, making the thesis dependent on growth rate sustainability.
Thesis pillars
- Fcf Positive Despite Gaap Losses→Stable
- Industry Leading Revenue Growth→Stable
- Consecutive Earnings Misses↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 27, 2026· older than 90 days
Natera, Inc. (NTRA) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Analyst target reached at $391.03 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6).
Natera applies cell-free DNA technology to diagnostics across oncology, women's health, and organ health. The company generated $2,306.1 million in revenue in 2025, processing about 3.5 million tests, with most revenues from Panorama NIPT, Horizon carrier screening, and... Read more
Sell if holding. Analyst target reached at $391.03 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.5/10, moderate confidence.
Passes 5/7 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: aggressive.
About Natera, Inc.
About Natera, Inc.
Natera generated $2,306.1 million in revenue in 2025, up from $1,696.9 million in 2024, with a net loss of $208.2 million and an accumulated deficit of $2.8 billion at December 31, 2025. The significant majority of revenues derives from three products: Panorama non-invasive prenatal testing, Horizon carrier screening, and Signatera tumor-informed circulating tumor DNA testing. The company processed approximately 3.5 million tests in 2025, up from 3.1 million in 2024.
Natera earns revenue from laboratory testing services billed to commercial insurance, Medicare, and Medicaid payers. Panorama—launched in 2013 and now the market leader by volume in the United States for NIPT—screens for fetal chromosomal abnormalities from a maternal blood draw as early as nine weeks of pregnancy. Signatera is custom-designed per patient from tumor tissue to track circulating tumor DNA; it holds Medicare coverage across colorectal, bladder, breast, and ovarian cancer as well as non-small cell lung cancer surveillance, and carries Breakthrough Device Designation from the FDA. Horizon carrier screening covers up to 835 inherited conditions. Illumina supplies the sequencers and reagents required for test processing; the 10-K discloses Illumina as both a key supplier and a NIPT competitor through its subsidiary Verinata Health. Bioinformatics algorithms run primarily on the DNAnexus platform hosted on AWS, with no backup cloud platform disclosed.
Show full overview
The supplier-competitor overlap with Illumina poses a compounding risk: if Illumina restricts access to sequencing instruments or raises prices, Natera's test volumes could stall. The 10-K also notes that transitioning sequencing platforms could expose the company to claims of infringement of Illumina intellectual property rights, limiting practical substitutability. Separately, the DNAnexus platform hosts the majority of Natera's proprietary algorithms; any termination of that agreement would interrupt algorithmic processing for both internal labs and Constellation licensees, for which the company acknowledges no backup cloud platform exists.
See also: Healthcare · Diagnostics & Research
From Natera, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Nov 2, 2026Recent Developments — Natera, Inc.
Latest news
- NEWS Natera Drops 8.4% After Hours, Shedding ~$5 Billion in One Session - 24/7 Wall St. — 24/7 Wall St. Nov 2, 2026 negative
- NEWS A Look at Natera Inc (NTRA) After 5.0% Decline -- GF Value $222. - GuruFocus — GuruFocus Oct 30, 2026 negative
- NEWS Natera (NTRA) Stock Could Be 32% Below Fair Value On ESMO Data - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results? - TradingView — TradingView Oct 28, 2026 neutral
- NEWS Natera (NTRA) Posts Stronger Signatera Data, Is The Stock Fully Priced? - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
Latest item Nov 2, 2026 · Generated 2026-11-05T11:49:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $391.03 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $363.66. Score 5.5/10, moderate confidence.
Analyst target $374.75 reached (−4.2% from $391.03); no take-profit level is published. Prior stop was $363.66. Stop-loss: $363.66.
Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Expensive valuation.
Natera, Inc. trades at a P/E of N/A (forward -2198.8). TrendMatrix value score: 2.4/10. Verdict: Sell.
31 analysts rate NTRA, with a consensus score of 4.3/5. 22 analysts publish price targets averaging $416.
What does Natera, Inc. do?Natera applies cell-free DNA technology to diagnostics across oncology, women's health, and organ health. The company...
Natera applies cell-free DNA technology to diagnostics across oncology, women's health, and organ health. The company generated $2,306.1 million in revenue in 2025, processing about 3.5 million tests, with most revenues from Panorama NIPT, Horizon carrier screening, and Signatera MRD tests. CLIA-certified labs operate in Texas, California, and Colorado, with over 100 global laboratory and distribution partners.